Using circulating tumor DNA to predict treatment response in lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of circulating tumor DNA (ctDNA) monitoring compared to positron emission tomography-computed tomography (PET-CT) in predicting treatment responses in patients with primary mediastinal large B-cell lymphoma (PMBL) after two cycles of chemotherapy. By utilizing next-generation sequencing (NGS), the study seeks to identify patients who may not respond to standard chemotherapy regimens early in their treatment. The goal is to improve patient outcomes by allowing for more personalized treatment strategies based on the detection of minimal residual disease. This multicenter pilot project will provide valuable insights into the evolution of tumor clones during treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years of age,
* Suffering from a diffuse primary B lymphoma of the mediastinum, newly diagnosed locally on a biopsy with anatomopathological analysis according to the recommendations of the WHO 2016 classification of hematological malignancies,
* All stages (I-IV)
* All IPI scores (0-5)
* With mediastinal involvement,
* Untreated (apart from emergency corticosteroid therapy less than 2mg/kg/day for 7 days),
* Treatment with R-CHOP-14 or R-ACVBP with PET-CT guided strategy (delta SUVmax) to be initiated,
* Tumor fixation above liver background on pre-treatment FDG PET/CT/CT (Deauville score ≥4),
* Having signed the informed consent prior to any study procedure
* Affiliated or beneficiary of a social protection plan.

Exclusion Criteria:

* Patient who has already started chemotherapy treatment,
* Contraindication to FDG PET-CT,
* No mediastinal involvement,
* Positive HIV serology,
* Positive hepatitis B or C serology with positive viral load,
* Protected adult (under guardianship or curatorship),
* Pregnant or breastfeeding women,
* Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).

Where it's running

• Centre Henri Becquerel
  Rouen, France Recruiting
• Centre Hospitalier Lyon Sud
  Lyon, France Not yet recruiting

Study contacts

• Principal investigator: Vincent Camus, Md — Centre Henri Becquerel
• Study coordinator: Vincent Camus, Md
• Email: vincent.camus@chb.unicancer.fr
• Phone: +33232082497

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• Comparing advanced and classical immunotherapy for lymphoma treatment

  This study is testing whether newer immunotherapy treatments for high-grade B cell lymphoma work better and are safer than traditional methods for adults who have already had treatment that didn't work.

  Recruiting at 2 sites Seoul St. Mary's Hospital · Seoul and 1 other locations · NCT06796517

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Epcoritamab for B-cell lymphoma patients not fully responding to CAR-T therapy

  This study is testing if a new treatment called epcoritamab can help people with B-cell lymphoma who didn't fully respond to CAR-T therapy feel better and improve their chances of survival.

  Recruiting Phase 2 Academic and Community Cancer Research United · Rochester, Minnesota and 5 other locations · NCT06238648

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.